home / stock / algs / algs news

ALGS News and Press, Aligos Therapeutics Inc. From 10/30/23

Stock Information
Company Name: Aligos Therapeutics Inc.
Stock Symbol: ALGS
Market: NASDAQ
Website: aligos.com
Menu
ALGS ALGS Quote ALGS Short ALGS News ALGS Articles ALGS Message Board
Get ALGS Alerts

News, Short Squeeze, Breakout and More Instantly...
ALGS - Aligos Therapeutics director buys shares worth $6M

2023-10-30 07:06:31 ET More on Aligos Therapeutics Aligos Therapeutics stock plummets on $92M private placement financing Seeking Alpha’s Quant Rating on Aligos Therapeutics Historical earnings data for Aligos Therapeutics Financial information for Ali...
ALGS - Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that announced that it will repo...

ALGS - Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that an abstract for its capsid ...

ALGS - Aligos Therapeutics stock plummets on $92M private placement financing

2023-10-23 14:33:47 ET More on Aligos Therapeutics Seeking Alpha’s Quant Rating on Aligos Therapeutics Historical earnings data for Aligos Therapeutics Financial information for Aligos Therapeutics For further details see: Aligos Therapeutics stock...
ALGS - Aligos Therapeutics Announces $92 Million Private Placement Financing

Proceeds expected to fund the following: - NASH (ALG-055009): top line data from Phase 2a study (Q4 2024) - Hepatitis B/CAM-E (ALG-000184): Phase 2 enabling activities (H2 2024) - Funding expected to extend cash runway through end of 2025 SOUTH SAN FRANCISCO, Calif., Oct. ...

ALGS - Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558

- NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies - This is the second NIH-funding received to advance the development of ALG-097558 - First in human Phase 1 study evaluating single/multiple doses of ALG...

ALGS - Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced it has ...
ALGS - Aligos Therapeutics GAAP EPS of -$0.43 beats by $0.06, revenue of $2.59M

2023-08-03 17:59:34 ET Aligos Therapeutics press release ( NASDAQ: ALGS ): Q2 GAAP EPS of -$0.43 beats by $0.06 . Revenue of $2.59M (-29.8% Y/Y). For further details see: Aligos Therapeutics GAAP EPS of -$0.43 beats by $0.06, revenue of $2.59M

ALGS - Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and fina...

ALGS - Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023

SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral disea...
Previous 10 Next 10